JP2024507996A5 - - Google Patents

Info

Publication number
JP2024507996A5
JP2024507996A5 JP2023552220A JP2023552220A JP2024507996A5 JP 2024507996 A5 JP2024507996 A5 JP 2024507996A5 JP 2023552220 A JP2023552220 A JP 2023552220A JP 2023552220 A JP2023552220 A JP 2023552220A JP 2024507996 A5 JP2024507996 A5 JP 2024507996A5
Authority
JP
Japan
Prior art keywords
protein
plasmid
seq
cells
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/018027 external-priority patent/WO2022183072A1/en
Publication of JP2024507996A publication Critical patent/JP2024507996A/ja
Publication of JP2024507996A5 publication Critical patent/JP2024507996A5/ja
Pending legal-status Critical Current

Links

JP2023552220A 2021-02-26 2022-02-25 リンパ球を標的とするレンチウイルスベクター Pending JP2024507996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154639P 2021-02-26 2021-02-26
US63/154,639 2021-02-26
PCT/US2022/018027 WO2022183072A1 (en) 2021-02-26 2022-02-25 Lymphocyte targeted lentiviral vectors

Publications (2)

Publication Number Publication Date
JP2024507996A JP2024507996A (ja) 2024-02-21
JP2024507996A5 true JP2024507996A5 (cg-RX-API-DMAC7.html) 2025-03-03

Family

ID=80780729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552220A Pending JP2024507996A (ja) 2021-02-26 2022-02-25 リンパ球を標的とするレンチウイルスベクター

Country Status (11)

Country Link
US (4) US20240218390A1 (cg-RX-API-DMAC7.html)
EP (1) EP4298114A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507996A (cg-RX-API-DMAC7.html)
KR (1) KR20230160242A (cg-RX-API-DMAC7.html)
CN (1) CN117203223A (cg-RX-API-DMAC7.html)
AU (1) AU2022227021A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017213A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212006A1 (cg-RX-API-DMAC7.html)
IL (1) IL305411A (cg-RX-API-DMAC7.html)
MX (1) MX2023009910A (cg-RX-API-DMAC7.html)
WO (1) WO2022183072A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212006A1 (en) * 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
US12565647B2 (en) 2021-05-28 2026-03-03 The Regents Of The University Of California Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes
TW202334405A (zh) 2021-12-15 2023-09-01 美商英特瑞斯生物療法公司 假型分型之病毒顆粒、包含其之組合物及其用途
WO2024026284A2 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
CA3266895A1 (en) * 2022-09-12 2024-03-21 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITION AND METHOD OF UNIVERSAL PSEUDOTYPE RETROVIRUSES
CN117802163A (zh) * 2022-09-30 2024-04-02 深圳市济因生物科技有限公司 靶向载体及其制备方法与用途
CN120457212A (zh) * 2022-11-04 2025-08-08 优莫佳生物制药股份有限公司 展示融合分子的慢病毒颗粒及其用途
US20260176651A1 (en) * 2022-11-04 2026-06-25 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
WO2024145622A1 (en) * 2022-12-29 2024-07-04 Kelonia Therapeutics, Inc. Recombinant retroviruses, compositions, and methods of use
WO2024145593A1 (en) * 2022-12-29 2024-07-04 Kelonia Therapeutics, Inc. Recombinant retrovirus, compositions, and methods of use
WO2024145605A1 (en) * 2022-12-29 2024-07-04 Kelonia Therapeutics, Inc. Recombinant retroviruses, compositions, and methods of use
US20260218136A1 (en) * 2022-12-29 2026-07-30 Kelonia Therapeutics, Inc. Recombinant retrovirus, compositions, and methods of use
EP4680753A2 (en) * 2023-03-17 2026-01-21 Kelonia Therapeutics, Inc. Dual targeted gene therapy
WO2024207008A2 (en) * 2023-03-30 2024-10-03 Kelonia Therapeutics, Inc. In vivo lentivirus animal models
EP4696704A4 (en) * 2023-04-10 2026-07-15 Shenzhen Genocury Biotech Co Ltd VSVG MUTANT AND TARGETING VECTOR
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024238153A1 (en) * 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
IL325668A (en) * 2023-06-30 2026-02-01 Esobiotec Sa Viral vector and producer cell
WO2025011662A1 (zh) * 2023-07-12 2025-01-16 深圳市济因生物科技有限公司 一种载体和体外转染非激活t细胞的方法
CN121443745A (zh) * 2023-07-25 2026-01-30 深圳市济因生物科技有限公司 一种病毒载体及tcr亚基的应用
WO2025036498A1 (zh) * 2023-08-16 2025-02-20 深圳市济因生物科技有限公司 一种病毒载体及其在感染b细胞中的应用
EP4784626A1 (en) 2023-09-25 2026-08-05 Kelonia Therapeutics, Inc. Antigen binding polypeptides
IL327310A (en) 2023-09-25 2026-05-01 Kelonia Therapeutics Inc Cancer treatment vehicles
CN116987157B (zh) * 2023-09-27 2023-11-28 深圳华大生命科学研究院 一种弹状病毒包膜蛋白、含其的靶向慢病毒载体及其应用
WO2025149068A1 (zh) * 2024-01-10 2025-07-17 深圳市济因生物科技有限公司 一种病毒颗粒及其制备方法与应用
WO2025178803A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California Compositions and methods for targeted delivery of nucleic acid-binding effector polypeptides
WO2025203091A2 (en) * 2024-03-26 2025-10-02 Micro Crispr Pvt. Ltd. Surface modification of lentiviral particle and producer cell thereof
WO2026026586A1 (zh) * 2024-08-01 2026-02-05 深圳市济因生物科技有限公司 一种包含多种靶向分子的载体及提高载体转导效率的方法
CN119174831A (zh) * 2024-11-26 2024-12-24 中国医学科学院医学实验动物研究所 基于冠状病毒Spike与hACE2互作介导的细胞特异性基因递送系统

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ATE368122T1 (de) 1999-04-29 2007-08-15 Cell Genesys Inc Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8008268B2 (en) 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
EP1975239A1 (en) 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
EP2019144A1 (en) 2007-07-23 2009-01-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vector particles for targeting CD34+ cells
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
EP3202903B1 (en) 2010-12-22 2020-02-12 President and Fellows of Harvard College Continuous directed evolution
WO2014016383A2 (en) 2012-07-25 2014-01-30 Theravectys Glycoproteins for pseudotyping lentivectors
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
JP6412579B2 (ja) 2014-01-10 2018-10-24 シリオン・バイオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 偽型レンチウイルスベクター
AU2015209540B2 (en) 2014-01-21 2021-05-13 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive T-cell immunomonitoring
US10072067B2 (en) 2014-01-30 2018-09-11 Children's Hospital Medical Center Fetal hemoglobin for genetic correction of sickle cell disease
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
CN106456670B (zh) 2014-04-25 2020-01-07 蓝鸟生物公司 制备过继性细胞疗法的改善方法
US9759689B2 (en) 2014-05-02 2017-09-12 The Regents Of The University Of Michigan Real-time detection and imaging of terahertz pulse radiation by using photoacoustic conversion
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US11970707B2 (en) 2017-09-18 2024-04-30 Children's Hospital Medical Center Strong insulator and uses thereof in gene delivery
GB201715052D0 (en) * 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
PT3684786T (pt) 2017-09-22 2024-10-30 Centre Nat Rech Scient Glicoproteína mutante do vírus da estomatite vesicular
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
AU2019397152A1 (en) 2018-12-14 2021-06-24 2Seventy Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020234810A1 (en) 2019-05-20 2020-11-26 Instituto De Biologia Experimental E Tecnológica (Ibet) Modified envelope glycoproteins for retroviridae viral vector pseudotyping and process for obtaining it
CN114127305A (zh) 2019-05-23 2022-03-01 麻省理工学院 经由逆转录病毒表面展示的配体发现和基因递送
CA3212006A1 (en) 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
US20220340876A1 (en) 2021-04-16 2022-10-27 Massachusetts Institute Of Technology Viral targeting of hematopoietic stem cells
TW202334405A (zh) 2021-12-15 2023-09-01 美商英特瑞斯生物療法公司 假型分型之病毒顆粒、包含其之組合物及其用途

Similar Documents

Publication Publication Date Title
AU2019299439B2 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
JP7699154B2 (ja) 腫瘍微小環境を逆転させる融合タンパク質及びその使用
US20240425565A1 (en) Chimeric Natural Killer Cell Receptors and Method of Using Thereof
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
JP2021532742A5 (cg-RX-API-DMAC7.html)
JP2020506700A5 (cg-RX-API-DMAC7.html)
US11760806B2 (en) CD-38 directed chimeric antigen receptor constructs
CN110461335A (zh) 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
JP2023527530A (ja) 同種異系移植のための操作された免疫細胞
JP2018527014A5 (cg-RX-API-DMAC7.html)
JP2021514631A5 (cg-RX-API-DMAC7.html)
JP7723420B2 (ja) B細胞標的化並列CAR(pCAR)治療的薬剤
US20210261646A1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
JP2024525815A5 (cg-RX-API-DMAC7.html)
US12534509B2 (en) Engineered immune cells with receptor cross-talk
JP2025536940A (ja) 新規cd19バインダー、それを含むcar-t構造体、およびその使用方法
CN117683139A (zh) 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
WO2018045034A1 (en) Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
TW202430565A (zh) 包含與il18組合之新穎cd19結合體之car-t構築體及其使用方法
JP2023544836A (ja) Cd19に指向されたキメラ抗原受容体構築物
JP2024534499A (ja) Il5ra細胞表面マーカー
WO2025218739A1 (en) Polypeptide systems
TW202615663A (zh) 用於生產治療性構築體之載體
EA050762B1 (ru) Аллогенные терапевтические клетки
WO2025191154A1 (en) Therapeutic agents